BTIG Research Boosts Vaxcyte (NASDAQ:PCVX) Price Target to $160.00

Vaxcyte (NASDAQ:PCVX) had its price objective raised by BTIG Research from $98.00 to $160.00 in a research report report published on Tuesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research firms also recently weighed in on PCVX. Needham & Company LLC increased their price objective on Vaxcyte from $95.00 to $140.00 and gave the company a buy rating in a report on Tuesday. Cantor Fitzgerald reiterated an overweight rating on shares of Vaxcyte in a research report on Thursday, June 20th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte presently has an average rating of Buy and a consensus target price of $131.83.

Vaxcyte Trading Up 2.7 %

Shares of PCVX stock opened at $112.10 on Tuesday. The business’s 50-day moving average price is $81.08 and its 200-day moving average price is $73.28. Vaxcyte has a 12 month low of $44.20 and a 12 month high of $119.27. The firm has a market capitalization of $12.20 billion, a price-to-earnings ratio of -26.19 and a beta of 0.97.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.12). During the same period last year, the business posted ($0.70) EPS. On average, sell-side analysts predict that Vaxcyte will post -4.33 earnings per share for the current fiscal year.

Insider Activity at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 10,000 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $111.93, for a total transaction of $1,119,300.00. Following the completion of the sale, the chief operating officer now directly owns 207,503 shares in the company, valued at approximately $23,225,810.79. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Vaxcyte news, COO Jim Wassil sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $111.93, for a total value of $1,119,300.00. Following the transaction, the chief operating officer now directly owns 207,503 shares of the company’s stock, valued at $23,225,810.79. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Grant Pickering sold 15,000 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $75.64, for a total value of $1,134,600.00. Following the transaction, the chief executive officer now owns 478,888 shares in the company, valued at $36,223,088.32. The disclosure for this sale can be found here. Insiders have sold a total of 85,283 shares of company stock worth $7,271,218 over the last quarter. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Vaxcyte

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in shares of Vaxcyte by 15.2% during the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock worth $665,152,000 after purchasing an additional 1,284,883 shares in the last quarter. RA Capital Management L.P. raised its stake in Vaxcyte by 4.0% during the 1st quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company’s stock worth $560,398,000 after buying an additional 312,500 shares during the period. Janus Henderson Group PLC boosted its holdings in Vaxcyte by 9.9% in the first quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock worth $524,117,000 after acquiring an additional 692,492 shares in the last quarter. Capital Research Global Investors grew its stake in Vaxcyte by 20.4% in the first quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock valued at $282,839,000 after acquiring an additional 700,414 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Vaxcyte by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock valued at $216,966,000 after acquiring an additional 498,359 shares in the last quarter. 96.78% of the stock is owned by institutional investors.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.